Literature DB >> 31487521

Bringing Order out of Chaos: Establishing an Epistatic Relationship between CD33 and TREM2.

Timothy Y Huang1, Huaxi Xu2.   

Abstract

TREM2 and CD33 are microglial receptors associated with Alzheimer's disease (AD) risk. In this issue of Neuron, Griciuc et al. (2019) demonstrate opposing effects of CD33 and TREM2 on AD phenotypes, where CD33 deletion promotes neuroprotection in a manner dependent on TREM2.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31487521      PMCID： PMC7224407          DOI： 10.1016/j.neuron.2019.08.019

Source DB:  PubMed          Journal:  Neuron        ISSN： 0896-6273            Impact factor:   17.173


  10 in total

1.  TREM2 Maintains Microglial Metabolic Fitness in Alzheimer's Disease.

Authors:  Tyler K Ulland; Wilbur M Song; Stanley Ching-Cheng Huang; Jason D Ulrich; Alexey Sergushichev; Wandy L Beatty; Alexander A Loboda; Yingyue Zhou; Nigel J Cairns; Amal Kambal; Ekaterina Loginicheva; Susan Gilfillan; Marina Cella; Herbert W Virgin; Emil R Unanue; Yaming Wang; Maxim N Artyomov; David M Holtzman; Marco Colonna
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

2.  Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.

Authors:  Ana Griciuc; Alberto Serrano-Pozo; Antonio R Parrado; Andrea N Lesinski; Caroline N Asselin; Kristina Mullin; Basavaraj Hooli; Se Hoon Choi; Bradley T Hyman; Rudolph E Tanzi
Journal:  Neuron       Date:  2013-04-25       Impact factor: 17.173

3.  TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function.

Authors:  Yingjun Zhao; Xilin Wu; Xiaoguang Li; Lu-Lin Jiang; Xun Gui; Yan Liu; Yu Sun; Bing Zhu; Juan C Piña-Crespo; Muxian Zhang; Ningyan Zhang; Xiaochun Chen; Guojun Bu; Zhiqiang An; Timothy Y Huang; Huaxi Xu
Journal:  Neuron       Date:  2018-03-07       Impact factor: 17.173

4.  Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer's Disease Models.

Authors:  C Y Daniel Lee; Anthony Daggett; Xiaofeng Gu; Lu-Lin Jiang; Peter Langfelder; Xiaoguang Li; Nan Wang; Yingjun Zhao; Chang Sin Park; Yonatan Cooper; Isabella Ferando; Istvan Mody; Giovanni Coppola; Huaxi Xu; X William Yang
Journal:  Neuron       Date:  2018-03-07       Impact factor: 17.173

5.  TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease.

Authors:  Ana Griciuc; Shaun Patel; Anthony N Federico; Se Hoon Choi; Brendan J Innes; Mary K Oram; Gea Cereghetti; Danielle McGinty; Anthony Anselmo; Ruslan I Sadreyev; Suzanne E Hickman; Joseph El Khoury; Marco Colonna; Rudolph E Tanzi
Journal:  Neuron       Date:  2019-07-10       Impact factor: 17.173

6.  Variant of TREM2 associated with the risk of Alzheimer's disease.

Authors:  Thorlakur Jonsson; Hreinn Stefansson; Stacy Steinberg; Ingileif Jonsdottir; Palmi V Jonsson; Jon Snaedal; Sigurbjorn Bjornsson; Johanna Huttenlocher; Allan I Levey; James J Lah; Dan Rujescu; Harald Hampel; Ina Giegling; Ole A Andreassen; Knut Engedal; Ingun Ulstein; Srdjan Djurovic; Carla Ibrahim-Verbaas; Albert Hofman; M Arfan Ikram; Cornelia M van Duijn; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

7.  TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model.

Authors:  Yaming Wang; Marina Cella; Kaitlin Mallinson; Jason D Ulrich; Katherine L Young; Michelle L Robinette; Susan Gilfillan; Gokul M Krishnan; Shwetha Sudhakar; Bernd H Zinselmeyer; David M Holtzman; John R Cirrito; Marco Colonna
Journal:  Cell       Date:  2015-02-26       Impact factor: 41.582

Review 8.  New insights into the role of TREM2 in Alzheimer's disease.

Authors:  Maud Gratuze; Cheryl E G Leyns; David M Holtzman
Journal:  Mol Neurodegener       Date:  2018-12-20       Impact factor: 14.195

9.  TREM2 variants in Alzheimer's disease.

Authors:  Rita Guerreiro; Aleksandra Wojtas; Jose Bras; Minerva Carrasquillo; Ekaterina Rogaeva; Elisa Majounie; Carlos Cruchaga; Celeste Sassi; John S K Kauwe; Steven Younkin; Lilinaz Hazrati; John Collinge; Jennifer Pocock; Tammaryn Lashley; Julie Williams; Jean-Charles Lambert; Philippe Amouyel; Alison Goate; Rosa Rademakers; Kevin Morgan; John Powell; Peter St George-Hyslop; Andrew Singleton; John Hardy
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

10.  CD33 modulates TREM2: convergence of Alzheimer loci.

Authors:  Gail Chan; Charles C White; Phoebe A Winn; Maria Cimpean; Joseph M Replogle; Laura R Glick; Nicole E Cuerdon; Katie J Ryan; Keith A Johnson; Julie A Schneider; David A Bennett; Lori B Chibnik; Reisa A Sperling; Elizabeth M Bradshaw; Philip L De Jager
Journal:  Nat Neurosci       Date:  2015-09-28       Impact factor: 24.884
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.